← All institutions

Bernstein

218 reports

Reports from this institution

Bernstein

Bernstein: China’s innovative drugs gain global clinical validation: Kelun and Hansoh report strong data, while Innovent’s first-line lung cancer treatment remains under scrutiny

Bernstein believes the key change at ESMO 2026 was that several drugs developed in China produced efficacy data in global studies. Kelun-Biotech achieved a positive global phase III result, while Hansoh’s early data sustained the efficacy seen in China; Innovent’s IBI363 faces tests of efficacy durability and safety.

Bernstein

Bernstein: Kweichow Moutai returns to growth in the third quarter as direct sales accelerate, while channel destocking continues to weigh on margins

iMoutai lifted the direct-sales share to 54%, but destocking in the premium liquor channel was slower than expected, and third-quarter revenue and earnings per share both missed Bernstein forecasts. The firm cut its target price but remains positive on the benefits of the channel mix and price increases once inventories stabilize.

Bernstein

Bernstein: Semiconductor valuations fall as earnings estimates rise: Why does Bernstein still see strong AI demand?

As of 30 October, the Philadelphia Semiconductor Index had fallen 27% from its June peak, while expected earnings per share for the next 12 months rose by about 40% over the same period. Bernstein believes cloud providers’ spending plans and Intel’s data center business continue to show strong AI demand, while the PC business is being held back by tight memory supplies.

Bernstein

Bernstein: US midterms approach: How great is the political risk to data center construction?

Bernstein estimates that 244 gigawatts of data center projects are exposed to political risk, based on gubernatorial candidates’ probabilities of winning, little changed from last month. The firm believes local economic interests could shift the policy focus toward requiring developers to bear more of the cost of electricity infrastructure.

Bernstein

Bernstein: Starbucks’ margin recovery accelerates: Cost leverage emerges alongside same-store growth

In the fourth quarter of fiscal 2026, U.S. same-store sales rose 7.7%, while North American operating margin increased 4.4 percentage points year over year. Bernstein believes slower cost growth and room for further savings support continued margin recovery, but sales transfers from store closures and the benefit of an extra week complicate the assessment of growth quality.